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Appraising descriptive and analytic findings of large cohort studies
Barnaby C Reeves, DPhil. Bristol Medical School, University of Bristol, England UK.
Large representative cohorts can provide compelling descriptions of variation in both health 
care practice and health outcomes, and their value is often underestimated. Such 
information is vital to health-policy makers for planning services, but also to clinicians and 
researchers, since substantial variation often represents an opportunity to target 
improvements in practice and influence future outcomes. In linked research, Devereaux and 
colleagues report  rates of perioperative mortality and serious complications after surgery1 
among people undergoing surgery and requiring at least one night in hospital, adjusted for 
baseline comorbidities. The scale of the VISION study (>40,000 participants recruited over 
six years) and the VISION collaboration (which spans six continents) is staggering. However, 
bias in analyses of observational studies is almost unavoidable and estimates of 
relationships between complications and mortality should be interpreted carefully before 
applying their findings to clinical and policy decisions.
Confidence in the results of any study starts with reviewing the authors’ prespecified 
objectives, ideally through registration details and a protocol. The VISION study was 
established with multiple aims and the registration details (NCT00512109) refer to prognostic 
analyses of troponin assays,2-4 making the origins of this report difficult to trace. A statistical 
analysis plan supplied by the authors in an appendix sets out six objectives, namely, to 
determine: the incidence of postoperative complications within 30 days after surgery; the 
time-dependent relationship between these complications and 30-day mortality; the 
attributable fraction of death at 30 days of each postoperative complication independently 
associated with mortality; the timing of death during the first 30-days after noncardiac 
surgery; the proportion of patients who died after noncardiac surgery in-hospital and 
separately after hospital discharge during a 30-day follow-up period; and the risk of death at 
30-days after noncardiac surgery by surgical category.
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Four objectives are descriptive while the second and third objectives require analytic 
quantification of associations between perioperative complications and 30-day mortality. 
For descriptive objectives, appraisal needs to focus on recruitment to the cohort and the 
quality and completeness of the dataset. The VISION study accounts for all patients 
determined as being eligible, showing that mortality was available for 99.9% (supplemental 
figure 1). Patients who did not consent made up only 25% of the total, with mainly logistical 
reasons explaining why others were not enrolled. Here, potential concern about the validity 
of the descriptive results might arise due to the varied methods of consenting patients across 
sites. For example, patients at differential risk of perioperative mortality or complications 
might have been excluded between admission and consent, and not be accounted for.
Findings for analytic objectives need particular scrutiny because several sources of bias can 
undermine their validity.5 Selection into the VISION cohort could also have biased 
quantification of associations between complications and mortality if patients were excluded 
for reasons related to the predictor of interest (the occurrence of a complication) and 
outcome (perioperative mortality).5 This might have arisen, albeit for a few patients, if a 
patient had a complication and died before retrospective consent could be sought.
It is important to consider whether residual confounding can explain the associations 
observed or bias their magnitude substantially.5 In the linked study, hazard ratios (HR) for 
associations between major bleeding and acute kidney injury with 30-day mortality, 
estimated with and without adjustment for preoperative haemoglobin and eGFR, suggest 
some residual confounding in the primary analyses (Supplemental Table 9). The HR for 
major bleeding (but not AKI) is reduced by adjusting for preoperative haemoglobin and the 
HR for AKI (but not major bleeding) is reduced by adjusting for preoperative eGFR. These 
shifts in the HRs are small compared to the overall magnitude of the HRs, so there is no 
reason to doubt that the associations are real; however, their magnitude may be more 
uncertain than indicated by their confidence intervals.
Page 2 of 5
For Peer Review Only
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential
Differential misclassification of predictors and outcomes5 can happen when outcomes are 
classified with knowledge of the predictors or vice versa. In the linked study, these risks 
seem unlikely, since definitions of complications were set out and applied to data that had 
already been collected, and complications that involved clinical judgement were adjudicated.
Missing data, for predictors, confounders or outcomes, can also introduce bias5 but, in the 
linked study, data were available for 99.0% of the entire cohort. This high percentage may 
be accounted for by the limited number of predictors included in the model, which in turn 
introduces the risk of residual confounding. Supplementary analyses adjusting for the 
additional risk factors preoperative Hb and eGFR show that these preoperative 
characteristics were missing for 3.4% and 6.8% of patients.
Finally, cherry-picking results from other results generated e.g., from multiple outcome 
measurements, multiple analyses of the predictor-outcome relationship or different 
subgroups5 is increasingly being recognised as a pervasive source of bias.6,7 It is notable 
that the authors of the linked study had a statistical analysis plan (many analyses of 
observational cohorts do not) but it is dated some years after recruitment ended (April 2017 
versus November 2013). There was no selection of results for multiple outcomes or different 
subgroups but selection of the reported results for relationships between complications and 
mortality cannot be excluded.
Estimates of the relationships between complications and mortality underpin the calculation 
of attributable fractions – if the former are uncertain due to potential bias, so are the latter. 
Attributable fractions should also be interpreted cautiously: basing clinical practice or policy 
decisions on these statistics requires the user to question closely the plausibility of the 
assumption that relationships between complications and 30-day mortality are entirely 
causal. I salute the achievement of the VISION study investigators but advise caution in 
applying the relationships of complications with 30-day mortality and the attributable 
fractions. 
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Word count: 933 (main text, with my edits)
Key points:
1. Descriptions of variation in health care practice and outcome provide extremely 
valuable information.
2. Estimation of associations between predictors and outcome are at risk of several 
biases, which must be careful appraised.
3. The credibility of attributable fractions depends on the validity of the associations on 
which they are based and the assumption that these associations are entirely causal.
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